Myomo to Report Third Quarter Financial Results on November 7, 2023
31 Octobre 2023 - 9:05PM
Business Wire
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the
“Company”), a wearable medical robotics company that offers
increased functionality for those suffering from neurological
disorders and upper-limb paralysis, today announced that it will
report financial results for the three and nine months ended
September 30, 2023 on November 7, 2023.
The Company will host a conference call the same day, Tuesday
November 7, 2023 at 4:30 p.m. ET with prepared remarks by Paul R.
Gudonis, chairman and chief executive officer, and David Henry,
chief financial officer.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will be given a
conference passcode and unique PIN to gain immediate access to the
call and bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time. Those
without internet access or unable to pre-register may dial in by
calling, 1-844-707-6932 (U.S.) or 1-412-317-9250 (International). A
webcast of the call may also be accessed at Myomo’s Investor
Relations page at http://ir.myomo.com/.
A replay of the webcast will be available beginning
approximately one hour after the completion of the live conference
call at http://ir.myomo.com/. A dial-in replay of the call will be
available until November 21, 2023; please dial 1-877-344-7529 (U.S.
toll free), 855-669-9658 (Canada toll free) or 1-412-317-0088
(International toll) and provide the access code 5227358.
About Myomo, Inc.
Myomo, Inc. is a wearable medical robotics company that offers
improved arm and hand function for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to support the arm and restore function to the
weakened or paralyzed arms of patients suffering from CVA stroke,
brachial plexus injury, traumatic brain or spinal cord injury, ALS
or other neuromuscular disease or injury. It is currently the only
marketed device that, sensing a patient’s own EMG signals through
non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are
able to return to work, live independently and reduce their cost of
care. Myomo is headquartered in Boston, Massachusetts, with sales
and clinical professionals across the U.S and representatives
internationally. For more information, please visit
www.myomo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031114683/en/
For Myomo: ir@myomo.com
Investor Relations: Kim Sutton Golodetz LHA Investor Relations
212-838-3777 kgolodetz@lhai.com
Myomo (AMEX:MYO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Myomo (AMEX:MYO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024